Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors,
chronic kidney disease, and the cardiovascular system and has profound impacts on …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked
increases in death and rehospitalization rates, which then decline exponentially though they …

It is well established that an elevated potassium level (hyperkalemia) is associated with a
risk of adverse events including morbidity, mortality and healthcare system cost …

Primary aldosteronism (PA) is an endocrinopathy characterized by dysregulated
aldosterone production that occurs despite suppression of renin and angiotensin II, and that …

ABSTRACT Aims Mineralocorticoid receptor antagonists (MRAs) improve outcomes in heart
failure with reduced ejection fraction (HFrEF) but remain underused and are often …

Potassium disorders are one of the most common electrolyte abnormalities in patients with
chronic kidney disease (CKD), contributing to poor clinical outcomes. Maintaining serum …

Heart failure with reduced ejection fraction (HFrEF) is a complex and progressive clinical
condition characterized by dyspnea and functional impairment. HFrEF has a high burden of …

Heart failure (HF) remains one of the most common causes of hospitalization and mortality
among Polish patient s. The position of the Section of Cardiovascular Pharmacotherapy …

Abstract Background Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-
proBNP Testing, of Heart Failure Therapies (STRONG-HF) demonstrated the safety and …